Loading…
Reported covered position: Committee on Ways and Means, Clerk, 2/2014-12/2014 Rep. Michael Bishop, LA and LD, 1/2015-4/2018
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Source: Senate LDA
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Discussions related to H.R.1, One Big Beautiful Bill Act (2025) Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Prohibiting Foreign Access to American Genetic Information Act of 2024
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
A bill to require a study on the national security implications of the People's Republic of China's efforts to create an official digital currency.
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws.
Discussions related to H.R.1, One Big Beautiful Bill Act (2025) Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill. H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. H.R.946, ORPHAN CURES Act, to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
General issues related to the manufacturing workforce
Trade-related public policy around tariffs and intellectual property, no related bills
Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Public policy related to the FDA including PDUFA, drug reviews, approval pathways, and clinical trials
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income
General issues related to the manufacturing workforce
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Biopharmaceutical innovation policy issues and supply chain International intellectual property and market access policy issues Trade-related aspects of Intellectual Property (TRIPS) Waiver General outbound investment policy issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Biopharmaceutical innovation policy issues and supply chain International intellectual property and market access policy issues Trade-related aspects of Intellectual Property (TRIPS) Waiver General outbound investment policy issues
Support stronger IP and exclusivity protections and enforcement in foreign markets Biopharmaceutical innovation and patent policy Bayh-Dole March-in rights, Patent thicket, and AI policy issues
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing S.1214, RARE Act S.3558, BioSecure Act General issues regarding Priority Review Voucher Reauthorization, no specific bill number
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovations and Jobs Act issues related to OECD negotiations on the taxation of global income
Support stronger IP and exclusivity protections and enforcement in foreign markets
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
General discussions regarding disability provisions in FAA Reauthorization legislation
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act Issues related to ALS
Support stronger IP and exclusivity protections and enforcement in foreign markets
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Discussions regarding pharmaceutical issues related to supply chain S.113, Prescription Pricing for the People Act of 2023 H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
Appropriations on mental health and Alzheiner's screening and diagnosis
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) Research and Development Tax Credit American Innovation and Jobs Act Tax Provisions of Budget Reconciliation
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation, including provisions related to corporate taxes, Medicare, and prescription drug pricing Mental Health Workforce Expansion The Mental Health Professionals Workforce Shortage Loan Repayment Act HELP Copays Act Issues related to ALS
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) International tax issues, including Pillar 1 and Pillar 2
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Discussions regarding coverage, coding, and reimbursement issues Policy proposals related to Medicare Part D and patient cost-sharing HHS drug policy issues and regulatory policy issues Draft National Coverage Determination on Alzheimer's treatments
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) International tax issues, including Pillar 1 and Pillar 2
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) International tax issues, including Pillar 1 and Pillar 2
Issues related to tax reform and tax policy Tax Cuts and Jobs Act of 2017 (P.L.115-97)
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis and appropriations, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act S.3558, BioSecure Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program Medicare reform
Support stronger IP and exclusivity protections and enforcement in foreign markets
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Appropriations on mental health and Alzheiner's screening and diagnosis
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) Issues related to OECD negotiations on the taxation of global income
Drug cost and pricing policy S.1967, PBM Act S.1542, DRUG Act H.R.5539, ORPHAN Cures Act Education and discussions regarding pharmaceutical issues related to supply chain H.R.830, HELP Copays Act
Support stronger IP and exclusivity protections and enforcement in foreign markets
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Drug cost and pricing policy issues Issues related to the 340B program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy issues Issues related to the 340B program
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) American Innovation and Jobs Act Issues related to OECD negotiations on the taxation of global income
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Support stronger IP and exclusivity protections and enforcement in foreign markets
Drug cost and pricing policy S.1339, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain S.1067, Ensuring Timely Access to Generics Act of 2023 S.1114, Expanding Access to Low Cost Generics Act of 2023 S.113, Prescription Pricing for the People Act of 2023 S.127, Pharmacy Benefit Transparency Act H.R.830, HELP Copays Act H.R.485, Protecting Health Care for All Patients Act
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, screening and diagnosis, PET scan coverage and reimbursement, and dementia care Inflation Reduction Act implementation (P.L.117-1769), including provisions related to corporate taxes, Medicare, research and development, and prescription drug pricing The Mental Health Professionals Workforce Shortage Loan Repayment Act S.1214, RARE Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Drug cost and pricing policy issues Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments Issues related to the 340B program
Appropriations on mental health screening and diagnosis
Drug cost and pricing policy S.127, Pharmacy Benefit Manager Transparency Act and other PBM reforms Discussions regarding pharmaceutical issues related to supply chain
Support stronger IP and exclusivity protections and enforcement in foreign markets
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Drug cost and pricing policy Patient affordability issues policy proposals related to clinical trial diversity Issues related to the 340B program
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Issues related to tax reform and tax policy Implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97) International tax issues, including Pillar 1 and Pillar 2
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination
Trade-related aspects of Intellectual Property (TRIPS) Waiver, no related bill number
Support stronger IP and exclusivity protections and enforcement in foreign markets Patent litigation reform issues and issues related to post-grant proceedings at the USPTO H.R.2891, Preserve Access to Affordable Generics and Bosimilars Act H.R.2873, Affordable Prescriptions for Patients through Promoting Competition Act of 2021 H.R.2883, Stop Stalling Access to Affordable Medications H.R.2884, Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S.2891, Restoring the America Invents Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to corporate taxes, Medicare, and prescription drug pricing CMS/NCD draft decision on monoclonal antibodies H.R.7667, Food and Drug Amendments of 2022 S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act User Fee Agreements, specifically reauthorization of PDUFA and BSUFA
Discussions regarding coverage, coding, and reimbursement issues Policy proposals related to Medicare Part D and patient cost-sharing HHS drug policy issues and regulatory policy issues Draft National Coverage Determination on Alzheimer's treatments
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE